High volumes with low prices are the keys...Eventually the prices for Vascepa will be cut in half and wholesale prices will also drop...European and China sales will boom...Competition in the CVD market will be unable to match the effectiveness, safety, and price of Vascepa.
Volume is the key to Amarin's success...New methods to increase the supply of EPA will come on line in order to satisfy the demand...This is just the beginning of a long ride for Vascepa and for Amarin.
Hamky, I didn't phrase my question properly. I don't have any concerns about the ability of Amarin to meet supply in the near term. My question was more about the current total API supply, and how that might effect a buyout. Amarin has the majority of global supply under contract. How do you see this factoring into a possible takeover? Sleven,
News 
Market Data 
Discover 
AI
